290 related articles for article (PubMed ID: 33038239)
21. Comparative efficacy and safety of secukinumab, ixekizumab, and tofacitinib in patients with active psoriatic arthritis showing insufficient response to tumor necrosis factor inhibitors.
Song GG; Lee YH
Int J Clin Pharmacol Ther; 2021 Jul; 59(7):511-518. PubMed ID: 33835018
[TBL] [Abstract][Full Text] [Related]
22. Effects of TNF-α inhibition
Elliott A; Wright G; Pendleton A; Rooney M
Ther Adv Musculoskelet Dis; 2023; 15():1759720X231179524. PubMed ID: 38024204
[TBL] [Abstract][Full Text] [Related]
23. Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study.
Fagerli KM; Lie E; van der Heijde D; Heiberg MS; Kalstad S; Rødevand E; Mikkelsen K; Lexberg AS; Kvien TK
Ann Rheum Dis; 2013 Nov; 72(11):1840-4. PubMed ID: 23562987
[TBL] [Abstract][Full Text] [Related]
24. Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA.
Brahe CH; Ørnbjerg LM; Jacobsson L; Nissen MJ; Kristianslund EK; Mann H; Santos MJ; Reino JG; Nordström D; Rotar Z; Gudbjornsson B; Onen F; Codreanu C; Lindström U; Möller B; Kvien TK; Pavelka K; Barcelos A; Sánchez-Piedra C; Eklund KK; Tomšič M; Love TJ; Can G; Ionescu R; Loft AG; van der Horst-Bruinsma IE; Macfarlane GJ; Iannone F; Hyldstrup LH; Krogh NS; Østergaard M; Hetland ML
Rheumatology (Oxford); 2020 Jul; 59(7):1640-1650. PubMed ID: 31665497
[TBL] [Abstract][Full Text] [Related]
25. Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter?
Lindström U; Bengtsson K; Olofsson T; Di Giuseppe D; Glintborg B; Forsblad-d'Elia H; Jacobsson LTH; Askling J
Ann Rheum Dis; 2021 Nov; 80(11):1445-1452. PubMed ID: 34130984
[TBL] [Abstract][Full Text] [Related]
26. Secukinumab retention rate is greater in patients with psoriatic arthritis presenting with axial involvement.
Adami G; Idolazzi L; Benini C; Fracassi E; Carletto A; Viapiana O; Gatti D; Rossini M; Fassio A
Reumatismo; 2023 May; 75(1):. PubMed ID: 37154254
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2.
McInnes IB; Chakravarty SD; Apaolaza I; Kafka S; Hsia EC; You Y; Kavanaugh A
RMD Open; 2019; 5(2):e000990. PubMed ID: 31565242
[TBL] [Abstract][Full Text] [Related]
28. Real-world Longterm Effectiveness of Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis Patients from the Rheumatic Diseases Portuguese Register.
Vieira-Sousa E; Eusébio M; Ávila-Ribeiro P; Khmelinskii N; Cruz-Machado R; Rocha TM; Bernardes M; Santos-Faria D; Silva JL; Santos H; Miguel C; Carvalho P; Costa T; Duarte AC; Meirinhos T; Nero P; Fonseca JE; Santos MJ
J Rheumatol; 2020 May; 47(5):690-700. PubMed ID: 31371659
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results.
Smolen JS; Siebert S; Korotaeva TV; Selmi C; Bergmans P; Gremese E; Joven-Ibáñez B; Katsifis G; Noël W; Nurmohamed MT; Richette P; Sfikakis PP; de Vlam K; Theander E; Gossec L
Ann Rheum Dis; 2021 Nov; 80(11):1419-1428. PubMed ID: 34162594
[TBL] [Abstract][Full Text] [Related]
30. Meta-analysis of IL-17 inhibitors in two populations of rheumatoid arthritis patients: biologic-naïve or tumor necrosis factor inhibitor inadequate responders.
Wu D; Hou SY; Zhao S; Hou LX; Jiao T; Xu NN; Zhang N
Clin Rheumatol; 2019 Oct; 38(10):2747-2756. PubMed ID: 31165341
[TBL] [Abstract][Full Text] [Related]
31. Sustained remission with methotrexate monotherapy after 22-week induction treatment with TNF-alpha inhibitor and methotrexate in early psoriatic arthritis: an open-label extension of a randomized placebo-controlled trial.
de Jong HMY; van Mens LJJ; Nurmohamed MT; Kok MR; van Kuijk AWR; Baeten DLP; van de Sande MGH
Arthritis Res Ther; 2019 Sep; 21(1):208. PubMed ID: 31521192
[TBL] [Abstract][Full Text] [Related]
32. Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis.
Schoels M; Aletaha D; Smolen JS; Wong JB
Ann Rheum Dis; 2012 Aug; 71(8):1303-8. PubMed ID: 22294630
[TBL] [Abstract][Full Text] [Related]
33. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry.
Glintborg B; Ostergaard M; Krogh NS; Andersen MD; Tarp U; Loft AG; Lindegaard HM; Holland-Fischer M; Nordin H; Jensen DV; Olsen CH; Hetland ML
Arthritis Rheum; 2013 May; 65(5):1213-23. PubMed ID: 23460467
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of biologics targeting interleukin-6, -12/23 and -17 pathways for peripheral psoriatic arthritis: a network meta-analysis.
Wu D; Yue J; Tam LS
Rheumatology (Oxford); 2018 Mar; 57(3):563-571. PubMed ID: 29244162
[TBL] [Abstract][Full Text] [Related]
35. Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies.
Coates LC; Wallman JK; McGonagle D; Schett GA; McInnes IB; Mease PJ; Rasouliyan L; Quebe-Fehling E; Asquith DL; Fasth AER; Pricop L; Gaillez C
Arthritis Res Ther; 2019 Dec; 21(1):266. PubMed ID: 31801620
[TBL] [Abstract][Full Text] [Related]
36. Time until onset of action when treating psoriatic arthritis: meta-analysis and novel approach of generating confidence intervals.
Pham PA; Dressler C; Eisert L; Nast A; Werner RN
Rheumatol Int; 2019 Apr; 39(4):605-618. PubMed ID: 30684041
[TBL] [Abstract][Full Text] [Related]
37. A real-world economic analysis of biologic therapies for psoriatic arthritis in Italy: results of the CHRONOS observational longitudinal study.
Zagni E; Frassi M; Mariano GP; Fusaro E; Lomater C; Del Medico P; Iannone F; Foti R; Limonta M; Marchesoni A; Raffeiner B; Viapiana O; Grassi W; Grembiale RD; Guggino G; Mazzone A; Tirri E; Perricone R; Sarzi Puttini PC; De Vita S; Conti F; Zullo A; Simoni L; Fiocchi M; Orsenigo R; Colombo D
BMC Health Serv Res; 2022 Dec; 22(1):1537. PubMed ID: 36527051
[TBL] [Abstract][Full Text] [Related]
38. Long-Term Efficacy of Tumor Necrosis Factor Inhibitors for the Treatment of Methotrexate-Naïve Rheumatoid Arthritis: Systematic Literature Review and Meta-Analysis.
Gulácsi L; Zrubka Z; Brodszky V; Rencz F; Alten R; Szekanecz Z; Péntek M
Adv Ther; 2019 Mar; 36(3):721-745. PubMed ID: 30637590
[TBL] [Abstract][Full Text] [Related]
39. Relative efficacy and safety of secukinumab and guselkumab for the treatment of active psoriatic arthritis: A network meta-analysis.
Song GG; Lee YH
Int J Clin Pharmacol Ther; 2021 Jun; 59(6):433-441. PubMed ID: 33860750
[TBL] [Abstract][Full Text] [Related]
40. Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries.
Michelsen B; Georgiadis S; Di Giuseppe D; Loft AG; Nissen MJ; Iannone F; Pombo-Suarez M; Mann H; Rotar Z; Eklund KK; Kvien TK; Santos MJ; Gudbjornsson B; Codreanu C; Yilmaz S; Wallman JK; Brahe CH; Möller B; Favalli EG; Sánchez-Piedra C; Nekvindova L; Tomsic M; Trokovic N; Kristianslund EK; Santos H; Löve TJ; Ionescu R; Pehlivan Y; Jones GT; van der Horst-Bruinsma I; Ørnbjerg LM; Østergaard M; Hetland ML
Arthritis Care Res (Hoboken); 2022 Jul; 74(7):1205-1218. PubMed ID: 33460531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]